A
Alcista
Alcista · 25%ANIP
$77.64
Precio del escenario
$72.290
+0.007 (+0.01%)Al cierre
Loading chart…
- Máximo
- 73.080
- Apertura
- 72.650
- Precio medio ponderado por volumen
- 72.29
- Volumen
- 333.93K
- Capitalización
- 1.32B
- Mínimo
- 71.500
- Importe
- 24.14M
- EV/EBITDA, TTM
- 6.07
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Análisis de IA of ANI Pharmaceuticals, Inc. (ANIP)
MantenerCurrently, ANI Pharmaceuticals Inc is trading at $72.29, which is below the average analyst price target of $98.75 (from Oppenheimer, Leerink, and Guggenheim). The forward P/E ratio of 7.12 indicates that the stock may be undervalued compared to its earnings potential. However, the stock has seen a significant decline of 24% over the past year, and insider selling has increased dramatically by 14497.26%, which raises concerns about future performance. Therefore, while the stock shows potential for recovery, the risks associated with insider selling and recent performance suggest a hold rather than a buy at this time.
Recomendaciones de analistas (3)
+59.08% de potencial alcista
Comprar
2 Comprar
1 Mantener
0 Vender
Actual: 72.29
Mínimo
100.00
Promedio
115.00
Máximo
124.00
Oppenheimer
Perform
$85
2026-09-23
Oppenheimer
2026-09-23
Precio objetivo
$85
Perform
Leerink
Superar al mercado
$104
2026-09-09
Leerink
2026-09-09
Precio objetivo
$104
Superar al mercado
Guggenheim
Comprar
$119
2026-08-10
Guggenheim
2026-08-10
Precio objetivo
$119
Comprar
Canaccord
Mantener
$90
2026-08-10
Canaccord
2026-08-10
Precio objetivo
$90
Mantener
Canaccord
Mantener
$91
2026-07-17
Canaccord
2026-07-17
Precio objetivo
$91
Mantener
Métricas de valoración
El PER previsto actual de ANI Pharmaceuticals, Inc. (ANIP) es 7.12, frente a su media de 5 años de 12.68.
Escenarios de precio de Alphio AI para ANIP
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ANIP en cartera
Cronología de eventos
Noticias
9.010-12NewsfilterANI Pharmaceuticals Reports Significant SYNCHRONICITY Trial Results
8.509-23NASDAQ.COMANI Pharmaceuticals Receives FDA Approval for New Drug
8.509-23NASDAQ.COMANI Pharmaceuticals Receives FDA Approval for New Drug
9.508-15Yahoo FinanceQ2 Performance Analysis: ANI Pharmaceuticals vs. Generic Peers
9.508-07Yahoo FinanceANI Pharmaceuticals Reports Record Q2 2026 Earnings Driven by Rare Disease Growth
Preguntas frecuentes sobre ANIP, respondidas por Alphio AI
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, ANI Pharmaceuticals Inc is trading at $72.29, which is below the average analyst price target of $98.75 (from Oppenheimer, Leerink, and Guggenheim). The forward P/E ratio of 7.12 indicates that the stock may be undervalued compared to its earnings potential. However, the stock has seen a significant decline of 24% over the past year, and insider selling has increased dramatically by 14497.26%, which raises concerns about future performance. Therefore, while the stock shows potential for recovery, the risks associated with insider selling and recent performance suggest a hold rather than a buy at this time.
3 analysts cover ANIP: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 115.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.